COPD Drugs Market in China to grow at a CAGR of 15.56% during 2016-2020: Key vendors GSK, Merck, Novartis, Almirall, Mylan, Orion, Prosonix
ResearchMoz added Latest Research Report titled " COPD Drugs Market in China 2016-2020 " to it's Large Report database.
About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China
Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=741902
The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.
Technavios analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.
Read All healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: COPD: An overview
Causes and risk factors
Symptoms
Diagnosis
Management
PART 06: China-Country snapshot
Social and economic conditions
Healthcare reform
Healthcare infrastructure
PART 07: Pharmaceutical industry in China
Market overview
Major pharmaceutical vendors in China
Opportunities for global and local vendors
Drug approval process in China
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://deep-research-report.blogspot.com/
About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China
Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=741902
The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.
Technavios analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.
Read All healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: COPD: An overview
Causes and risk factors
Symptoms
Diagnosis
Management
PART 06: China-Country snapshot
Social and economic conditions
Healthcare reform
Healthcare infrastructure
PART 07: Pharmaceutical industry in China
Market overview
Major pharmaceutical vendors in China
Opportunities for global and local vendors
Drug approval process in China
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://deep-research-report.blogspot.com/
COPD Drugs Market in China to grow at a CAGR of 15.56% during 2016-2020: Key vendors GSK, Merck, Novartis, Almirall, Mylan, Orion, Prosonix
![COPD Drugs Market in China to grow at a CAGR of 15.56% during 2016-2020: Key vendors GSK, Merck, Novartis, Almirall, Mylan, Orion, Prosonix]()
Reviewed by Sagar Jagtap
on
01:49
Rating:
No comments: